We searched 161 lenvatinib-related cholecystitis cases, and 54 cholangitis cases, among which five cases co-occurred adverse events of cholecystitis and cholangitis. Keywords: cholangitis; cholecystitis; lenvatinib pharmacovigilance EN cholangitis cholecystitis lenvatinib pharmacovigilance 579 581 3 01/23/23 20230201 NES 230201 Lenvatinib, an oral multi-targeted receptor tyrosine kinase inhibitor (TKI), has been approved to treat several types of cancer, including radioactive-iodine-refractory differentiated thyroid cancer (RAI-R DTC), advanced hepatocellular carcinoma, kidney cancer, and endometrial cancer.[1] Recently, events of lenvatinib-related cholecystitis were found in the clinical trial and real-world studies.[[2], [4]] In Japan, the Pharmaceuticals and Medical Devices Safety Information has added cholecystitis as the clinically significant adverse reaction. [Extracted from the article]